HK1215674A1 - 结合使用莫米松和奥洛他定治疗过敏性鼻炎 - Google Patents

结合使用莫米松和奥洛他定治疗过敏性鼻炎 Download PDF

Info

Publication number
HK1215674A1
HK1215674A1 HK16103630.2A HK16103630A HK1215674A1 HK 1215674 A1 HK1215674 A1 HK 1215674A1 HK 16103630 A HK16103630 A HK 16103630A HK 1215674 A1 HK1215674 A1 HK 1215674A1
Authority
HK
Hong Kong
Prior art keywords
olopatadine
mometasone
combination
allergic rhinitis
treatment
Prior art date
Application number
HK16103630.2A
Other languages
English (en)
Chinese (zh)
Inventor
Neelima Khairatkar Joshi
Abhay Kulkarni
Dinesh Pradeep WALE
Vikram Mansingh BHOSALE
Piyush Agarwal
Patrick Keohane
Sudeesh K. TANTRY
Chad OH
Original Assignee
Glenmark Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited filed Critical Glenmark Pharmaceuticals Limited
Publication of HK1215674A1 publication Critical patent/HK1215674A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16103630.2A 2013-10-04 2014-10-03 结合使用莫米松和奥洛他定治疗过敏性鼻炎 HK1215674A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
INMM31742013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Publications (1)

Publication Number Publication Date
HK1215674A1 true HK1215674A1 (zh) 2016-09-09

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103630.2A HK1215674A1 (zh) 2013-10-04 2014-10-03 结合使用莫米松和奥洛他定治疗过敏性鼻炎

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553B1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10646500B2 (en) * 2013-10-04 2020-05-12 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
AU2018260934B2 (en) * 2017-06-28 2023-10-19 Glenmark Specialty S.A. Dispensing device and pharmaceutical compositions for the treatment of rhinitis
HRP20250411T1 (hr) * 2018-02-23 2025-07-18 Glenmark Specialty S.A. Liječenje alergijskog rinitisa kod pedijatrijskih subjekata kombinacijom mometazona i olopatadina
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
ES2284531T3 (es) 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
BR0316203A (pt) * 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DK1814538T3 (da) 2004-11-24 2009-11-02 Alcon Inc Fremgangsmåde til administration af næsespray
BRPI0615032A2 (pt) * 2005-09-01 2011-04-26 Biolipox Ab composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição
US20120121653A1 (en) 2005-12-02 2012-05-17 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
JP5185109B2 (ja) 2006-04-21 2013-04-17 東興薬品工業株式会社 スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
RU2011101151A (ru) 2008-07-15 2012-07-20 Шеринг Корпорейшн (US) Интраназальные композиции, содержащие деконгестант и кортикостероид
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
AU2010273347B2 (en) 2009-07-17 2015-04-30 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2012094283A2 (en) 2011-01-04 2012-07-12 Ista Pharmaceuticals, Inc. Bepotastine compositions
MX2015005081A (es) 2012-10-25 2015-07-17 Novozymes As Metodo mejorado para el lavado manual de la vajilla.
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
MY191380A (en) 2013-09-13 2022-06-21 Glenmark Specialty Sa Stabilized fixed dose drug composition having mometasone and olopatadine
US10646500B2 (en) * 2013-10-04 2020-05-12 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Also Published As

Publication number Publication date
EP2922553A1 (en) 2015-09-30
JP2018123157A (ja) 2018-08-09
MY176808A (en) 2020-08-21
WO2015049665A1 (en) 2015-04-09
US10646500B2 (en) 2020-05-12
RU2015128496A3 (enExample) 2018-06-19
RU2686670C2 (ru) 2019-04-30
EP2922553B1 (en) 2026-05-06
US20150099725A1 (en) 2015-04-09
EP4272839A3 (en) 2024-01-03
ZA201504740B (en) 2016-10-26
JP6419195B2 (ja) 2018-11-07
PH12015502302B1 (en) 2016-02-15
MX2015009429A (es) 2015-10-09
RU2015128496A (ru) 2017-11-13
JP6768733B2 (ja) 2020-10-14
CN105792828A (zh) 2016-07-20
PH12015502302A1 (en) 2016-02-15
RU2019104453A (ru) 2019-03-28
CN112773808A (zh) 2021-05-11
UA120587C2 (uk) 2020-01-10
JP2020097624A (ja) 2020-06-25
JP2016531949A (ja) 2016-10-13
EP4272839A2 (en) 2023-11-08
MX2020003035A (es) 2020-07-22

Similar Documents

Publication Publication Date Title
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
IL260585B (en) Compositions and methods for treating retinal diseases
IL238432A0 (en) Methods and devices for the treatment of ocular diseases in human subjects
IL244668A0 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
EP3013407A4 (en) Medical treatment system and method of use
EP3071193A4 (en) Compositions and methods for treatment of ocular inflammation and pain
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
EP3084000A4 (en) Method of diagnosis and treatment
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
EP2967523A4 (en) Tissue and vascular closure devices and methods of use thereof
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
EP2970249A4 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
EP3068316A4 (en) Devices, kits and methods relating to treatment of facet joints
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3060259A4 (en) Methods of treating or preventing vascular diseases of the retina
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
HK1219690A1 (zh) 利用抗生素来治疗超重和肥胖患者感染的方法
EP3013425A4 (en) Treatment and diagnosis of ocular disease
ME03399B (me) DERIVATI 2-ARIL-4-HIDROKSI-1,3-TIAZOLA KORISNI KAO INHIBITORI TRPM8 U LEĆENJU NEURALGIJE, BOLA, COPD l ASTME